American Oncology Partners of Maryland (Bethesda)
The Center for Cancer & Blood Disorders - Bethesda
Bethesda, MD
Filters
Save & Share
Clear Filters
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
MDS Centers of Excellence
Accepting patients
ELEMENT-MDS
Phase 3 Clinical Trial Comparing Luspatercept VS Epoetin Alfa in Patients with Very Low – Intermediate Risk MDS Who Are Not Transfusion Dependent
Learn more- Erythroid Maturation Agent (EMA)
- Erythropoiesis-Stimulating Agent (ESA)
- Red Blood Cell Stimulant
- Phase 3
Accepting patients
PRT2527
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies
Learn more- Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
- Phase 1
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
SELECT MDS-1
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Learn more- Hypomethylating Agents (HMA)
- RAR-α / NR1B1
- Phase 3
Not currently accepting
IBI188
A Phase 1b Study Evaluating the Safety and Efficacy of IBI188 in Combination With Azacitidine in Subjects With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (MDS)
Learn more- Monoclonal Antibody
- Phase 1
Accepting patients
Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Learn more- Observational Trial
Accepting patients
AK117/Placebo with Azacitidine
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
Learn more- Monoclonal Antibody
- CD47
- Closed Label (Masked)
- Placebo
- Randomization
- Phase 2